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Association of smoking 
and cancer with the risk 
of venous thromboembolism: 
the Scandinavian Thrombosis 
and Cancer cohort
Benedikte Paulsen1, Olga V. Gran1, Marianne T. Severinsen2,3, Jens Hammerstrøm4,5, 
Søren R. Kristensen2,6, Suzanne C. Cannegieter7, Hanne Skille1, Anne Tjønneland8, 
Frits R. Rosendaal7, Kim Overvad9, Inger Anne Næss10, John‑Bjarne Hansen1,11 & 
Sigrid K. Brækkan1,11*
Smoking is a well‑established risk factor for cancer, and cancer patients have a high risk of venous 
thromboembolism (VTE). Conflicting results have been reported on the association between smoking 
and risk of VTE, and the effect of smoking on VTE‑risk in subjects with cancer is scarcely studied. 
We aimed to investigate the association between smoking and VTE in subjects with and without 
cancer in a large population‑based cohort. The Scandinavian Thrombosis and Cancer (STAC) cohort 
included 144,952 participants followed from 1993–1997 to 2008–2012. Information on smoking 
habits was derived from self‑administered questionnaires. Active cancer was defined as the first two 
years following the date of cancer diagnosis. Former smokers (n = 35,890) and those with missing 
information on smoking status (n = 3680) at baseline were excluded. During a mean follow up of 
11 years, 10,181 participants were diagnosed with cancer, and 1611 developed incident VTE, of 
which 214 were cancer‑related. Smoking was associated with a 50% increased risk of VTE (HR 1.49, 
95% CI 1.12–1.98) in cancer patients, whereas no association was found in cancer‑free subjects (HR 
1.07, 95% CI 0.96–1.20). In cancer patients, the risk of VTE among smokers remained unchanged 
after adjustment for cancer site and metastasis. Stratified analyses showed that smoking was a risk 
factor for VTE among those with smoking‑related and advanced cancers. In conclusion, smoking was 
associated with increased VTE risk in subjects with active cancer, but not in those without cancer. Our 
findings imply a biological interaction between cancer and smoking on the risk of VTE.
Venous thromboembolism (VTE), a collective term for deep vein thrombosis (DVT) and pulmonary embolism 
(PE), is a common disease associated with substantial morbidity and  mortality1,2. Cancer is established as one 
of the leading risk factors for VTE, as cancer patients have a four- to sevenfold increased risk of  VTE3,4, and 
20–30% of all incident VTE-events are cancer-related5.
Cigarette smoking is recognized as a leading cause of preventable deaths in high-income  countries6, and 
today, approximately one billion of the world’s population are daily  smokers7. The harmful effects of smoking 
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on the risk of cancer and cardiovascular disease are well established. Smoking is a risk factor for several types of 
cancer including lung, esophageal, laryngeal, oral cavity, renal and bladder  cancers8.
Previous studies investigating the association between smoking and VTE have shown conflicting results. Sev-
eral studies have reported no association between smoking status and risk of  VTE9–12, whereas other studies have 
indicated an increased risk of VTE among current and former  smokers13, among current smokers  only14,15, and 
among heavy smokers  only16–19. In a recent meta-analysis of cohorts with validated VTE-events, current smoking 
was associated with a 20% increased risk of provoked  VTE20. This observation may suggest that the association 
between smoking and VTE is largely mediated through development of other comorbidities. Accordingly, heavy 
smoking was associated with increased risk of VTE in the Tromsø Study, but this association disappeared in 
cause-specific analyses where cancer and myocardial infarction were taken into  account21.
Smoking has been shown to interact with other inherited and acquired risk factors for VTE such as pro-
thrombotic  mutations13,22, oral  contraceptives13,  pregnancy23–26, and  surgery27. Likewise, cancer is known to 
act synergistically with prothrombotic  mutations28, various blood  parameters29,30, comorbid  conditions31 and 
hematopoietic growth  factors32 on the risk of VTE. Both smoking and cancer are known to influence the hemo-
static system separately via several mechanisms including increased levels of coagulation factors and fibrinogen, 
impaired fibrinolysis, endothelial dysfunction and increased platelet  aggregation33,34. It is likely to assume that 
coagulation abnormalities arising from two distinct acquired sources could increase the risk of VTE. However, 
the separate effects of smoking on the risk of VTE in subjects with and without cancer has thus far not been 
investigated. Therefore, using the Scandinavian Thrombosis and Cancer (STAC) cohort, a large population-based 
cohort with over 144,000 unique individuals, we aimed to investigate the effects of smoking on the risk of VTE 
in participants with and without cancer.
Methods
Study population. The Scandinavian Thrombosis and Cancer (STAC) cohort is comprised of three large 
population-based cohorts with enrolment from 1993 to 1997. The STAC cohort consists of the fourth survey 
of the Tromsø Study (Tromsø 4, Norway), the second Nord-Trøndelag Health Study (HUNT2, Norway) and 
the Diet, Cancer and Health Study (DCH, Denmark). The three individual  cohorts35–37 and the STAC  cohort38 
have previously been described in detail. In Tromsø 4, all inhabitants ≥ 25 years living in the municipality of 
Tromsø were invited and 27,158 (77%) participated. In the HUNT 2 Study, all residents of the Nord-Trøndelag 
county ≥ 20 years were invited to take part in the survey, and 65,237 (69%) participated. In the DCH Study, 
inhabitants aged 50 to 64 years living in the urban areas of Copenhagen and Aarhus, without a previous can-
cer were invited to participate, and 57,054 (35%) attended. Study participants were followed up from the day 
of inclusion in the individual cohorts (1993–1997) until the end of follow-up (2007–2012). Participants with 
a pre-baseline cancer or VTE diagnosis were excluded before merging the cohorts, yielding a study popula-
tion of 144,952 individuals in the STAC cohort. Further, subjects with missing information on smoking habits 
(n = 3680), as well as subjects reporting to be formers smokers at baseline (n = 35,890) were excluded. The study 
cohort, therefore, consisted of 105,382 participants aged 19 to 101 years.
The regional committees for research ethics in Norway and Denmark approved the respective cohort studies 
and the collaboration study. All participants in the cohorts provided informed written consent before inclusion. 
All methods were performed in accordance with the relevant guidelines and regulations.
We chose to merge the three cohorts and perform individual data analysis because the structure of the 
individual cohorts, the assessment of outcomes (VTE registrations), and the cancer registries in Norway and 
Denmark were quite homogenous. Harmonization of the data before merging and close control of the models 
further reduced heterogeneity, and the pooled individual data approach would yield higher statistical power 
than a meta-analysis approach.
Baseline measurements. Baseline information on lifestyle and cardiovascular risk factors was collected 
by means of physical examination and self-administered questionnaires. Body weight and height were measured 
in subjects wearing light clothing and no shoes. Body mass index (BMI) was calculated as the weight in kilo-
grams (kg) divided by the square of the height in meters (m). Information regarding self-reported diabetes, level 
of education (basic school, high school, and university/college) and lifestyle factors, including smoking habits, 
physical activity level and alcohol consumption was collected by self-administered questionnaires. Alcohol con-
sumption was defined as the reported average number of units per week. Information on smoking habits was 
also collected from the questionnaires. Smoking status was categorized into never smokers and current smokers. 
Current smokers were further dichotomized into categories according to amount of daily smoking; < 15 ciga-
rettes per day; and ≥ 15 cigarettes per day.
Identification of cancer. In the STAC cohort, all first lifetime diagnoses of cancer during follow-up were 
identified by linkage to the Danish Cancer Registry and the Cancer Registry of Norway. The unique national 
civil registration number assigned to all people residing in the Nordic countries was used for the  linkage38. The 
cancer registries receive information from general practitioners, hospital doctors, pathological laboratories, and 
death  certificates39,40, and provide information on date of cancer diagnosis, primary site of disease (ICD10 codes 
C00-96), tumor histology (ICO-3) and metastasis (localized, regional, distant, or unknown). Both cancer regis-
tries are considered high quality, and evaluations have reported a 98.8% completeness in Norway and 95–98% in 
Denmark, with histological verification of 94% and 93% diagnoses,  respectively39,40.
Identification and validation of venous thromboembolism. All symptomatic, objectively con-
firmed, first lifetime VTE events that occurred during follow-up were recorded after thorough identification 
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and validation. Potential cases of VTE were identified by searching discharge diagnosis registries, radiology 
procedure registries, cause of death registries and autopsy registries at each of the hospitals covering the study 
sites, as previously  described38. The medical records of each potential VTE case were reviewed by trained medi-
cal professionals, and adjudicated using similar confirmatory criteria in each cohort. A VTE event was only 
included if traditional signs and symptoms of DVT and/or PE were noted in the medical records, objective diag-
nostic tests confirmed the diagnosis of VTE (e.g. compression ultrasonography, venography, spiral computed 
tomography, perfusion-ventilation scan, pulmonary angiography, or autopsy) and appropriate treatment was 
initiated. In Tromsø and DCH the autopsy registries were also searched. Events identified through the autopsy 
registry were included if VTE was noted as the cause of death or as a significant condition contributing to death 
on the death certificate. Detailed description regarding VTE identification and validation in each of the three 
cohorts has been published  previously10,15,41. VTE events were classified as either a DVT or PE, and if the two 
events occurred concurrently, the event was registered as a PE.
Statistical analysis. Statistical analysis was performed using STATA version 14 (Stata Corporation LP, Col-
lege Station, Texas, USA). Participants were followed from the date of inclusion in one of the cohorts until the 
date of an incident VTE, emigration, death or end of follow-up (Dec 31, 2012 in Tromsø, December 31, 2007 in 
HUNT 2, and April 30, 2008 in DCH). Cancer was entered as a time-varying co-variate in the analysis. Thus, 
participants who developed cancer during follow-up contributed with person-time to the “no cancer” category 
from the date of inclusion until the date of cancer diagnosis, and thereafter in the “cancer” category until two 
years after the cancer diagnosis (active cancer time). VTE-events occurring during this two-year period were 
considered to be cancer-related. Participants who were alive and VTE-free at the end of the active cancer period 
were censored, as extending the observation period could potentially result in dilution of the results due to lack 
of information on cancer remission and relapses during follow-up.
The median follow-up time with inter quartile range (IQR) was calculated using descriptive statistics. Inci-
dence rates (IR) were calculated by dividing the total number of events by the person-time at risk and expressed 
as number of events per 1000 person-years. Cancer-exposed person-time was calculated from the date of cancer 
diagnosis and onwards (until VTE, migration, death or censoring two years after cancer diagnosis, as described 
above). Cox proportional hazard regression models were used to estimate hazard ratios (HR) with 95% confi-
dence intervals (CI) across categories of baseline smoking status in participants with and without cancer. The risk 
was assessed in two adjustment models. Model 1 included age, sex and BMI. Model 2 was additionally adjusted 
for cancer site and metastasis. The proportional hazards assumption was tested using Schoenfeld residuals.
To further investigate whether an effect on VTE in smokers with cancer could be explained by a higher 
proportion of thrombogenic cancer types in smokers, we stratified our data into smoking-related cancer sites 
and cancer sites that was not related to smoking. The classification smoking-related cancer was based on the 
International Agency for Research on Cancer (IARC) monograph about the causal association between tobacco 
use and  cancer8. Smoking-related cancers were defined as lung, urinary tract (urether and bladder), kidney, 
renal pelvis, ENT (= ear, nose and throat; nasal- and oral cavity, sinuses, middle ear, pharynx), larynx, lung, 
oesophagus, stomach, colorectal, pancreas and liver. Of note, acute myeloid leukaemia (AML) is related to smok-
ing, but as our data lacked stratification on type of leukaemia, AML could not be included in the definition of 
smoking-related cancer.
We also wanted to explore whether the relationship between smoking and VTE could be explained by more 
advanced cancers in smokers. We therefore stratified our analyses according to the degree of metastasis (local, 
regional, distant and unknown).
For the clinical interpretation of this paper, we investigated the risk of VTE according to smoking status in 
patients with overt cancer (i.e., from the date of cancer diagnosis). However, since VTE can be the first sign 
of an underlying (occult) malignancy, we also performed sensitivity analyses where we defined active cancer 
as the period 6 months before to 2 years after the VTE diagnosis and rerun the main analysis. Moreover, since 
VTE may not be related to cancer in those successfully cured after a short treatment period, we performed a 
second sensitivity analysis restricted to cancer patients with distant metastasis (i.e., non-curable disease) followed 
throughout the entire study period.
Results
Characteristics, assessed at cohort enrolment, in participants of the entire cohort (n = 105,382) and those who 
developed cancer during follow-up (n = 10,181) are presented in Table 1. The mean age at inclusion was 51 years 
and 44% of the participants were men. As expected, those who developed cancer were generally older (58 years 
vs. 51 years) and more often smokers (55% vs 46%) when compared with the entire cohort.
During a median follow-up of 11.6 years (IQR: 10.6–12.3), 1611 developed an incident VTE, of which 214 
were related to active cancer. The incidence rate (IR) of VTE was 1.4 per 1000 person-years (PY) in the total 
cohort, and 14.1 per 1000 PY in patients with active cancer. Accordingly, the risk of VTE was eightfold (HR 8.27, 
95% CI 7.14–9.57) higher in patients with active cancer when compared to cancer-free subjects after adjustment 
for age and sex.
At the time of cancer diagnosis, 35.6% of cancers were localized, 24.3% had regional metastases, 15.4% 
had distant metastases, while the remaining 24.7% either had missing information on metastasis or used non-
traditional cancer staging (i.e., haematological cancers). Breast, prostate and colorectal cancers were the most 
frequent cancers in the study population. The distribution of cancer site and metastasis at cancer diagnosis among 
never smokers and smokers is presented in Table 2. Smokers tended to present with more advanced disease at 
cancer diagnosis, as 19.3% of the smokers and 10.5% of the never smokers had distant metastases at the time 
of cancer diagnosis. Among smokers, lung cancer was the most frequent cancer site accounting for 21.5% of 
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the cancers, while the corresponding proportion was only 2.2% among never smokers. In addition, urological 
(5.8% vs. 3.9%) and upper gastrointestinal (7.9% vs. 5.2%) cancers were more frequent among smokers than 
among never smokers.
IRs and HRs of VTE according to smoking status in participants with and without cancer are presented 
in Table 3. In cancer-free subjects, smoking was not associated with increased risk of VTE (HR 1.07, 95% CI 
0.96–1.20). In patients with active cancer, smokers had 50% higher VTE risk than never-smokers (HR 1.49, 95% 
CI 1.12–1.98), and further adjustment for cancer site and metastasis had negligible impact on the risk estimate 
(HR 1.43, 95% CI 1.07–1.91). Stratification on cancer sites particularly related to smoking, revealed that smoking 
was associated with a 1.3-fold higher risk of VTE among those who developed cancer at sites that were typically 
related to smoking (HR 1.32, 95% CI 0.89–1.96). In those who developed cancer types not typically related to 
Table 1.  Baseline characteristics of the entire cohort and subjects with active cancer. Values are numbers 
or percentages with numbers or means ± SD in parenthesis. Active cancer: period from six months before a 
cancer diagnosis until two years after. BMI body mass index, Daily smoking indicates smoking at the time of 
enrollment; diabetes mellitus;
Entire cohort Cancer
All Men Women All Men Women
n 105 382 46,756 58,626 10,181 4782 5399
Age, (years, mean ± SD) 51 ± 14 50 ± 13 51 ± 14 58 ± 10 59 ± 10 58 ± 10
BMI, (kg/m2, mean ± SD) 25.8 ± 4.1 26.1 ± 3.5 25.6 ± 4.5 26.1 ± 4.3 26.2 ± 3.7 25.9 ± 4.7
Daily smoking, % (n) 45.9 (48 341) 50.9 (23 833) 41.8 (24 508) 55.0 (5 602) 63.3 (3 028) 47.7 (2 574)
Diabetes, % (n) 2.2 (2 323) 2.3 (1 086) 2.1 (1 237) 3.6 (361) 3.7 (187) 3.3 (183)
Use of antihypertensives, % (n) 9.7 (10 243) 8.2 (3 843) 10.9 (6 400) 14.5 (1 453) 12.9 (619) 15.4 (834)
Alcohol intake (units/week) 5.7 ± 9.8 7.9 ± 12 6.7 ± 7.0 7.4 ± 12 10.3 ± 15 4.9 ± 7.8
Education level
 Basic School, % (n) 27.1 (28 628) 22.1 (10 325) 31.4 (18 303) 34.6 (3 468) 29.9 (1 433) 37.7 (2 035)
 High School, % (n) 48.8 (51 450) 48.9 (22 855) 49.1 (28 595) 46.1 (4 624) 44.3 (2 120) 46.4 (2 504)
 Collage/University, % (n) 21.5 (22 729) 27.5 (12 573) 17.4 (10 153) 17.2 (1 731) 22.5 (1 079) 12.1 (652)
Physical activity > 1 h/week, % (n) 27.4 (28 897) 32.3 (15 229) 23.3 (13 668) 21.4 (2 145) 24.2 (1 160) 18.2 (985)
Table 2.  Distribution of cancer site and metastasis in smokers and never-smokers. Values are percentages with 
numbers in parenthesis. *Includes oesophagus, stomach, small intestine, liver, gallbladder and biliary tract 
cancers. ENT Ear, nose and throat, CNS central nervous system.
Never-smokers Smokers
Subjects, n 4 579 5 602
Age (years), mean ± SD 60 ± 11 58 ± 9
Cancer site
 ENT, % (n) 1.3 (58) 2.6 (143)
 Upper GI*, % (n) 3.9 (177) 5.8 (326)
 Colorectal, % (n) 16.2 (742) 11.4 (638)
 Pancreas, % (n) 2.3 (107) 3.1 (176)
 Lung, % (n) 2.2 (102) 21.5 (1205)
 Melanoma, % (n) 5.6 (257) 2.6 (144)
 Gynaecological, % (n) 9.2 (421) 4.4 (245)
 Breast, % (n) 20.9 (961) 12.7 (711)
 Urological, % (n) 5.2 (238) 7.9 (442)
 Prostate, % (n) 15.3 (700) 13.0 (726)
 CNS, % (n) 3.9 (180) 2.7 (151)
 Hem/lymph, % (n) 9.0 (411) 6.1 (341)
 Other, % (n) 4.4 (200) 5.2 (294)
 Missing 0.5 (25) 0.3 (15)
Metastasis
 Localized, % (n) 38.5 (1 762) 33.3 (1 865)
 Regional, % (n) 24.5 (1 120) 24.2 (1 358)
 Distant metastasis, % (n) 10.5 (483) 19.3 (1 082)
 Unknown, % (n) 26.5 (1214) 23.2 (1297)
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smoking, current smoking was not associated with increased risk of VTE (Table 4). Moreover, smoking was 
associated with increased VTE risk in cancer patients with regional- (HR 1.53, 95% CI 0.89–2.64) and distant 
metastasis (HR 1.69, 95% CI 0.97–2.96) (Table 5).
In cancer-free subjects, the VTE risk according to smoking was 0.93 (95% CI 0.80–1.10) in men and 1.22 
(95% CI 1.04–1.42) in women (Supplementary Table 1). In cancer patients, the risk estimate for VTE according 
to smoking status was 1.68 in women (95% CI 1.15–2.45) and 1.30 in men (95% CI 0.85–2.00), and persisted after 
multivariable adjustment for age, sex, BMI, cancer site and metastasis. Analyses of the daily quantity of cigarettes 
smoked (never smoker, < 15 cigarettes daily and ≥ 15 cigarettes daily) showed that an increase in quantity of daily 
smoking (at a threshold of 15 cigarettes daily) had little influence on the risk of VTE (Supplementary Table 2). 
Our sensitivity analyses showed that smoking remained a risk factor for VTE in cancer patients (HR 1.30, 95% 
CI 1.01–1.67) when the active cancer period was extended to include the period 6 months before diagnosis (i.e., 
occult cancer), and in analyses restricted to those with distant metastasis with unlimited follow-up (HR 2.05, 
95% CI 1.21–3.49) (Supplementary table 3).
Table 3.  Incidence rates and hazard ratios of venous thromboembolism (VTE) according to cancer and 
smoking status. CI confidence intervals, HR hazard ratio, IR incidence rates presented per 1000 person-years; 
Model 1: Adjusted for age, sex and BMI; Model 2: Adjusted for age, sex, BMI and cancer site and metastasis. 
Cancer was entered as a time-varying covariate in our models. Cancer-exposed person-time was calculated 
from the date of cancer diagnosis until a VTE, migration, death or end of the active cancer period (two years 
after cancer diagnosis).
VTE IR (95% CI) Model 1 HR (95%CI) Model 2 HR (95%CI)
VTE
No cancer
 Never smoker 814 1.3 (1.2–1.4) Ref –
 Current smoker 583 1.1 (1.0–1.2) 1.07 (0.96–1.20) –
Cancer
 Never smoker 87 12.6 (10.2–15.6) Ref Ref
 Current smoker 127 17.3 (14.5–20.6) 1.49 (1.12–1.98) 1.43 (1.07–1.91)
DVT
No cancer
 Never smoker 465 0.7 (0.6–0.8) Ref –
 Current smoker 349 0.6 (0.5–0.7) 1.11 (0.96–1.28) –
Cancer
 Never smoker 53 7.7 (5.9–10.1) Ref Ref
 Current smoker 76 10.4 (8.2–13.0) 1.50 (1.04–2.15) 1.50 (1.03–2.21)
PE
No cancer
 Never smoker 345 0.5 (0.5–0.6) Ref –
 Current smoker 223 0.4 (0.3–0.5) 0.98 (0.82–1.17) –
Cancer
 Never smoker 32 4.7 (3.3–6.6) Ref Ref
 Current smoker 47 6.4 (4.8–8.5) 1.47 (0.92–2.34) 1.39 (0.86–2.26)
Table 4.  Incidence rates and hazard ratios of venous thromboembolism (VTE) according to smoking status in 
patients with and without cancer types that are classified as smoking-related. Cancer types related to smoking 
were defined according to the International Agency for Research on Cancer (IARC), and included lung, 
urinary tract, kidney, renal pelvis, ENT (ear, nose and throat), larynx, lung, oesophagus, stomach, colorectal, 
pancreas, and liver. CI confidence intervals, HR hazard ratios, IR incidence rates presented per 1000 person-
years. Model 1: Adjusted for age, sex and BMI; Model 2: adjusted for age, sex, BMI and metastasis.
VTE IR (95% CI) Model 1 HR (95% CI) Model 2 HR (95% CI)
Patients with cancer types related to smoking
Never smoker 39 21.3 (15.6–29.1) Ref Ref
Current smoker 96 27.9 (22.8–34.0) 1.36 (0.92–2.02) 1.32 (0.89–1.96)
Patients with cancer types not related to smoking
Never smoker 48 9.5 (7.2–12.6) Ref Ref
Current smoker 31 8.0 (5.6–11.4) 0.96 (0.60–1.52) 0.94 (0.59–1.50)
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Discussion
In the present study, current smoking was associated with 50% increased risk of VTE in patients with active 
cancer. In contrast, smoking was not associated with VTE in cancer-free subjects. In cancer patients, the risk of 
VTE among current smokers remained unchanged after adjustments for cancer site and metastasis, suggesting 
that the effect was not explained by more advanced cancers in smokers than non-smokers. Moreover, smoking 
was associated with increased risk of VTE in those with cancer types that are typically related to smoking and 
in patients with regional- and distant metastasis.
As smoking increases blood coagulability and impairs endothelial function and  fibrinolysis33, it is etiologically 
sound to expect smoking to increase the risk of VTE. In our study, however, current smoking was not associated 
with an increased risk of VTE in cancer-free subjects. Accordingly, large population cohorts, such as the HUNT2 
 Study12, the Physicians’ Health  Study9, the Framingham  Study42, and the Longitudinal Investigation of Venous 
Thromboembolism (LITE)  Study11, also reported no increased risk of VTE related to smoking status. However, 
other studies have reported an increased risk of VTE among current and formers  smokers13, among current 
smokers  only14,15, and among heavy smokers  only16–19. Furthermore, some studies have reported an association 
only between smoking and provoked  VTE21,43. The diverging results could be attributed to differences in the dis-
tribution of patients with cancer and other co-morbid conditions associated with VTE. Taken together, the stud-
ies suggest that smoking alone is not sufficient to develop VTE, but when combined with some co-morbidities, 
such as cancer, smoking could result in a total risk factor level that exceeds the patient’s thrombosis threshold.
A few previous studies have reported an increased VTE risk in smokers with cancer. In a prospective obser-
vational study of 381 gastrointestinal or breast cancer patients receiving adjuvant chemotherapy, smoking (for-
mer and current) was associated with a twofold increased risk of  VTE44. In the Iowa Women’s Health Study, a 
cohort study of older women, the observed association between current and former smoking and risk of VTE 
was mainly driven by cancer-related VTEs among  smokers43. Further, results from the Tromsø Study, showed 
that heavy smoking (> 20 pack years) was associated with a 1.8-fold increased risk of provoked  VTE21, but the 
apparent association disappeared when intermediate development of cancer and myocardial infarction was 
taken into consideration. Our findings suggest that cancer patients who smoke have a higher risk of VTE than 
those who do not smoke.
A possible explanation for the combined effect of smoking and active cancer could be that smoking infer 
more advanced cancer (e.g. distant metastasis) and prothrombotic cancer types (e.g. lung cancer). Accordingly, 
smoking was associated with prothrombotic cancer types (e.g. lung, upper gastrointestinal and urological) and 
the proportion with distant metastasis was higher in smokers than in non-smokers in our study. However, the 
higher risk of VTE in cancer patients who smoked remained unchanged after adjustments for these factors, and 
smoking was also a risk factor for VTE in analyses restricted to cancer sites that were typically related to smok-
ing. Moreover, smoking was a risk factor for VTE also in analyses restricted to those with regional- and distant 
metastasis. This implies that the increased risk of VTE by smoking in cancer patients was not explained by more 
advanced cancer and prothrombotic cancer types in smokers. However, it is likely that more prothrombotic 
cancers (i.e. smoking-related cancers) contributes to exceeding the thrombosis threshold when combined with 
smoking. This could potentially explain why no association was observed in patients with cancers that were not 
related to smoking and those with localized cancer.
Smoking has previously been reported to interact with other acquired and inherited risk factors for VTE. 
Using the MEGA Study, Pomp and colleagues reported that both former and current smoking in combination 
with oral contraceptive use synergistically increased the risk of VTE in cancer-free  subjects13. In a prospective 
study of 56,014 participants in the DCH Study, heavy smoking and the non-O blood type demonstrated a posi-
tive interaction on the risk of VTE, with the joint effects being responsible for an additional 30.5 VTE events per 
100,000 person-years45. In addition, other studies have reported on the interaction between smoking and several 
risk factors for VTE including prothrombotic  mutations13,22,  pregnancy23–26, and  surgery27. Furthermore, previous 
studies have demonstrated that cancer also acts synergistically with several inherited and acquired risk factors 
Table 5.  Incidence rates and hazard ratios of venous thromboembolism (VTE) according to smoking status in 
cancer patients with localized, regional and distant metastasis, respectively.
VTE IR (95% CI) Model 1 HR (95% CI) Model 2 HR (95% CI)
Cancer patients with localized metastasis
Never smoker 22 7.3 (4.8–11.1) Ref Ref
Current smoker 21 7.0 (4.5–10.7) 1.04 (0.56–1.94) 1.09 (0.58–2.03)
Cancer patients with regional metastasis
Never smoker 22 13.4 (8.8–20.4) Ref Ref
Current smoker 38 21.7 (15.8–29.8) 1.53 (0.89–2.64) 1.50 (0.87–2.59)
Cancer patients with distant metastasis
Never smoker 19 40.6 (25.9–63.6) Ref Ref
Current smoker 47 61.3 (46.1–81.6) 1.69 (0.97–2.96) 1.66 (0.94–2.93)
Cancer patients with unknown metastasis
Never smoker 24 13.6 (9.1–20.1) Ref Ref
Current smoker 21 11.7 (7.6–17.9) 1.07 (0.57–1.98) 1.08 (0.58–2.03)
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for  VTE28–32. In the present study, smoking was associated with VTE only in cancer patients, which indicates a 
biological interaction between smoking and cancer on the VTE risk. Smoking results in widespread systemic 
effects in the body causing changes to both hemostatic and inflammatory  processes33,34, and the procoagulant 
nature of cancer is well-established34. Thus, it is likely to assume that a biological interaction between smoking 
and cancer on risk of VTE could be mediated via procoagulant changes arising from two sources.
The increased risk of VTE among cancer patients who smoked encourage recommendation of smoking 
cessation in order to avoid VTE in cancer patients. Current risk prediction scores for cancer-related VTE are 
based on clinical (e.g. cancer site, BMI) and laboratory (e.g. hemoglobin levels, platelet and leukocyte counts) 
parameters, and are thought to have limited clinical utility as they have a poor ability to distinguish between 
patients at high and low risk of  VTE46. Our finding of smoking as a risk factor for VTE in cancer may suggest 
to include smoking status in the development of future prediction models of VTE risk, particularly in patients 
with cancer types that are likely related to smoking.
The main strength of our study was the large sample size and comprehensive information at baseline, which 
enabled etiological analysis where potential confounders could be accounted for. The completeness and validity 
of the cancer registries in Norway and Denmark is very  high39,40. The study also had some limitations. Assess-
ment of tobacco exposure was obtained at baseline inclusion in the respective cohorts, and changes in smoking 
habits could potentially result in misclassification of exposure during follow-up. However, data from the DCH 
five-year follow-up questionnaires showed that 80% of smokers maintained the same smoking  status22, and, in 
all three cohorts, changes in smoking status in the population were towards lower tobacco  use36,47. In our sta-
tistical models, we assumed that smokers diagnosed with cancer continued to smoke. However, it is likely that 
some would quit smoking after being diagnosed with cancer. Changes in smoking status would likely result in 
an underestimation of the association between smoking and VTE due non-differential misclassification and, 
consequently, regression dilution bias. Unfortunately, we did not have information on type of cancer treatment. 
However, treatment choice would probably not be influence by smoking status, but rather be dependent on the 
type and advancement of the cancer. In stratified analyses, we showed that smoking was associated with risk of 
VTE both in those with cancer sites typically related to smoking, and when restricted to those with regional or 
distant metastasis.
In conclusion, current smoking was associated with 50% increased risk of VTE in subjects with cancer, 
whereas smoking was not associated with VTE risk in subjects without cancer. The predictive impact of smoking 
on VTE in cancer patients should be investigated in future studies.
Data availability
The data can be made available upon request to the steering committees of the different study cohorts.
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